ADMA Biologics stock
ADMANASDAQADMA Biologics, Inc., HealthcareISIN US0008991046
71Score 71 out of 100, Strong
Price and trend
75 / 100
Price history
−20% in one yearThe chart shows daily closes over 13 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 23% above it.
Since February 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Overheated: the price has risen very quickly lately (RSI 70).
The price is 35% below its 52-week high. Largest decline in 13 years: 91% (November 2014 to October 2021).
Chart figures for advanced users
- SMA 50$10.49
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$10.74
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)70
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$7.60
- The lowest closing price of the last twelve months.
- Resistance$20.38
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- ADMA Biologics, Inc. belongs to the Biotechnology industry (United States) and, with a market value of $2.94B, is number 106 of 296 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $510.17M (up 19.6% year on year) and earnings of $146.93M (down 25.7%).
- For fiscal 2026, analysts expect on average revenue of $536.68M (up 5.2%) and adjusted earnings per share of $0.82 (up 25.4%).
Show more
- MEQIRI Score 71 out of 100 (Strong): rank 110 of 714 in Healthcare, median 53.
- The P/E is 16.4 (Biotechnology median 21.3, own median of recent years 24.8).
- Our model puts fair value at $20.22, with the price 35% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Growing faster than its industryRevenue up 64.6% a year since 2020, Biotechnology median 19.7%.Growth 70
- High return on capitalReturn on invested capital 38.6% in fiscal 2025, Biotechnology median −24.3%.Profitability 96
- High marginNet margin 35.1% over the last 12 months, Biotechnology median −93.3%.Profitability 96
Weaknesses
- DilutionShare count up 177% since 2020.Capital allocation 54
- Volatile share priceVolatility 59% a year over the last 12 months.
Its standout strengths are profitability and valuation, while fundamentals holds the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk high
How well MEQIRI warnsOne of the 30% with the highest crash risk among smaller stocks.
From 2016 to 2025, 36 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- high price swings
- weak fundamentals
- price far below its 52-week high
Valuation
Valuation signal
Significantly undervaluedClosing price of 11 Nov 2026, used by the daily score.
In our model the price counts as cheap below $14.44 and expensive above $33.70 (uncertainty high, based on the price swings of the past year).
The two parts of the fair value come to $23.24 (cash-flow model) and $17.20 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is below both.
Calculated with a cost of equity of 9.5%. At 10.5% the fair value would be $18.36, at 8.5% it would be $22.88.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (21.3).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 6.3% on the twelve months before. Revenue turned from negative at the start of the period to positive ($510.17M in the latest year).
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 57%, operating 38%, net 29%. Last 12 months: net 35%.
Debt & balance sheet
latest quarterThe balance sheet is solid, with moderate debt and comfortable interest coverage.
Earnings
- Next earnings
- 24 Feb 2027in 104 days
- Last reported
- 4 Nov 2026EPS reported $0.23 (expected $0.20)above expectations
Analyst estimates
- Earnings per share
- $0.82+2.3%
- Revenue
- $536.68M+0.2%
- Earnings per share
- $0.89−5.7%
- Revenue
- $616.09M−2.1%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: +12.9%2026 guidance reiterated: revenue of $530 million to $560 million, adjusted EBITDA of $265 million to $300 million, adjusted net income of $170 million to $200 million.
“We continue to expect total revenue of $530 million to $560 million, adjusted EBITDA of $265 million to $300 million and adjusted net income of $170 million to $200 million.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 5 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
One insider bought on the open market in the last 6 months, $50,624 in total. One insider sold, $1.76M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at ADMA Biologics
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 71
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- VericelVCEL $3.03B66
- Xeris Biopharma HoldingsXERS $3.02B56
- XencorXNCR $3B46
- Zai LabZLAB $2.98B49
- MBX BiosciencesMBX $2.87B47
- BioArcticBIOA-B.ST $2.81B60
- Arcus BiosciencesRCUS $2.71B30
- Bavarian NordicBAVA.CO $2.69B71
ETFs that hold ADMA Biologics
Held by 15 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares Healthcare Innovation UCITS ETF2B78 | 0.30% | 0.40% | €1.49B |
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 0.19% | 0.35% | €1.21B |
| iShares S&P SmallCap 600 UCITS ETFIUS3 | 0.13% | 0.30% | €2.28B |
Show 5 more
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.10% | 0.30% | €2.17B |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.10% | 0.30% | €4.22B |
| L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ | 0.09% | 0.30% | €185.82M |
| iShares MSCI World Small Cap UCITS ETFIUSN | 0.03% | 0.35% | €8.19B |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.03% | 0.43% | €2.48B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 6 Nov 2026)
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.